Bibliographic Info
GuidelineConsolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations
Year of Publication2022
Issuing InstitutionWHO
Recommendation
Status
Maintained
Recommended in favor
Conditional
Certainty of evidence
Moderate
WHO recommends the use of pan-genotypic direct-acting antiviral (DAA) regimens for treatment of all adults, adolescents and children aged 3 years and above with chronic hepatitis C virus infection, regardless of stage of disease. Adults (18 years and above)
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection
Year2018
InstitutionWorld Health Organization